rom-1 Antibody

What is ROM-1 and why is it important in retinal research?

ROM-1 (Retinal Outer Segment Membrane Protein 1, also known as TSPAN23) is a transmembrane protein belonging to the tetraspanin superfamily. It is predominantly expressed in photoreceptor outer segment disc membranes and plays crucial roles in rod photoreceptor viability and disc morphogenesis regulation. ROM-1 is essential for proper organization of rod outer segments (ROS) and maintenance of ROS disc diameter. ROM-1 typically functions in conjunction with peripherin-2 (PRPH2), and mutations affecting these proteins are associated with various retinal degenerative disorders, making ROM-1 an important target for vision research .

What are the key applications for ROM-1 antibodies in research?

ROM-1 antibodies have demonstrated utility in several experimental applications, including:

• Western Blot (WB): Used at dilutions of 1:500-1:3000 to detect ROM-1 in tissue lysates

• Immunohistochemistry (IHC): Applied to identify ROM-1 expression patterns in tissue sections

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Employed at 1:20-1:200 dilutions to visualize cellular localization

• ELISA: Used for quantitative detection of ROM-1 protein levels

These applications are supported by numerous publications demonstrating ROM-1 antibody efficacy across human, mouse, and rat samples .

What are the optimal conditions for using ROM-1 antibodies in Western blot applications?

For Western blot applications, ROM-1 antibodies should be optimized as follows:

• Sample preparation: Eye tissues (particularly retina) or cultured cells expressing ROM-1

• Recommended dilution: 1:500-1:3000, though optimal dilution may be sample-dependent

• Detection systems: Both chemiluminescent and fluorescent secondary antibodies are suitable

• Controls: Include positive controls such as mouse or rat eye tissue lysates

• Molecular weight markers: Ensure markers cover the 35-50 kDa range to accurately identify ROM-1

• Blocking: 5% non-fat milk or BSA in TBST is typically effective

Researchers should note that ROM-1 complexes may display different migration patterns under reducing versus non-reducing conditions, which can be informative when studying ROM-1 oligomerization .

What protocol is recommended for immunofluorescence with ROM-1 antibodies?

For immunofluorescence applications using ROM-1 antibodies:

• Fix cells using 4% PFA for 15-20 minutes at room temperature

• Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes

• Block with 5% normal serum (matching secondary antibody host) for 30-60 minutes

• Incubate with primary ROM-1 antibody at 1:20-1:200 dilution overnight at 4°C

• Wash thoroughly with PBS (3-5 times)

• Apply fluorophore-conjugated secondary antibody for 1-2 hours at room temperature

• Counterstain nuclei with DAPI if desired

• Mount using anti-fade mounting medium

As demonstrated in published research, ROM-1 typically localizes to the outer segments of photoreceptors in retinal tissue and may show specific subcellular localization patterns in cultured cells .

How can ROM-1 antibodies be validated for specificity in experimental systems?

Rigorous validation of ROM-1 antibodies should include:

• Western blot comparison of wild-type tissues versus ROM-1 knockout samples

• Peptide competition assays to confirm epitope specificity

• Cross-validation using multiple antibodies targeting different ROM-1 epitopes

• Immunoprecipitation followed by mass spectrometry to confirm target identity

• Confirmation of expected tissue expression patterns (e.g., high expression in retinal photoreceptors)

• Correlation of expression changes in ROM-1 knockout/knockdown models

These validation approaches are particularly important when studying ROM-1 in complex disease models where altered expression or localization may be subtle .

How does ROM-1 deletion affect photoreceptor biology in mouse models?

Studies of ROM-1 knockout (ROM1−/−) mice have revealed several important phenotypes:

• Compensatory increase in PRPH2 expression levels to maintain total tetraspanin content

• Delayed disc maturation and increased outer segment diameter

• Absence of disc incisures (normal indentations in disc rims)

• Altered PRPH2 oligomerization with approximately 50% increase in monomeric PRPH2

• Changes in protein complex formation as revealed by velocity sedimentation analysis

These findings suggest that while ROM-1 is not absolutely required for disc formation, it plays important roles in regulating disc morphology and size. The compensatory increase in PRPH2 indicates functional redundancy between these tetraspanins in certain contexts .

How do ROM-1 and PRPH2 interact in normal retina versus disease states?

In normal retina, ROM-1 and PRPH2 form heteromeric complexes essential for proper disc rim formation and maintenance of photoreceptor outer segment structure. These proteins interact through conserved cysteine residues that form disulfide bonds, enabling the formation of higher-order oligomeric complexes.

In disease states:

• Mutations in PRPH2 can lead to various retinal dystrophies, with phenotypic severity often modulated by ROM-1

• When ROM-1 is eliminated in mice carrying the Y141C-PRPH2 mutation, the phenotype converts from a cone-rod dystrophy pattern to a retinitis pigmentosa pattern

• Some ROM-1 mutations by themselves are not pathogenic but can cause digenic retinitis pigmentosa when combined with certain PRPH2 mutations

• Analysis of protein complexes using non-reducing SDS-PAGE and velocity sedimentation reveals altered complex formation in disease models

This intricate relationship highlights the importance of considering ROM-1 as a potential disease modifier in PRPH2-associated retinal degenerations .

What evidence exists for ROM-1 involvement in non-retinal tissues and disorders?

While ROM-1 is primarily known for its role in retinal photoreceptors, recent research has identified potential roles in other tissues:

• Expression has been detected in annulus fibrosus (AF) of intervertebral discs

• Lower ROM-1 expression has been observed in degenerated AF

• ROM-1 may be relevant in intervertebral disc degeneration (IVDD) pathogenesis

• Single gene set enrichment analysis (GSEA) has been employed to explore the underlying mechanisms

This emerging evidence suggests that ROM-1 may have broader biological functions beyond the retina, potentially involving common cellular processes shared between photoreceptor disc membranes and other specialized cellular structures .

What are common issues when detecting ROM-1 by Western blot and how can they be resolved?

When working with ROM-1 antibodies in Western blot applications, researchers may encounter:

Researchers should note that ROM-1 forms complexes with PRPH2, which can result in complex banding patterns under non-reducing conditions. Using DTT can help consolidate these bands into monomeric forms for more straightforward interpretation .

How can ROM-1 protein complexes be effectively analyzed in research studies?

For comprehensive analysis of ROM-1 protein complexes:

• Use velocity sedimentation on sucrose gradients to separate complexes by size

• Compare non-reducing and reducing conditions in SDS-PAGE to identify disulfide-dependent interactions

• Employ blue native PAGE (BN-PAGE) to preserve native protein complexes

• Perform co-immunoprecipitation with ROM-1 or PRPH2 antibodies to identify interacting partners

• Apply cross-linking approaches before solubilization to stabilize transient interactions

• Use quantitative proteomics to compare complex composition between wild-type and disease models

This multi-faceted approach has been successfully utilized to characterize the altered complex formation in ROM-1 knockout mice and various disease models, revealing important insights into tetraspanin biology .

What considerations should be made when using ROM-1 antibodies in immunohistochemistry of retinal tissues?

When performing immunohistochemistry with ROM-1 antibodies on retinal sections:

• Fixation method significantly impacts epitope accessibility (4% PFA for 1-4 hours often works well)

• Antigen retrieval may be necessary (citrate buffer, pH 6.0 at 95°C for 10-20 minutes)

• Section thickness should be optimized (10-14 μm is typically suitable)

• Autofluorescence can be problematic in retinal tissue (sodium borohydride treatment may help)

• Orientation of sections is critical for identifying outer segment localization

• Co-staining with rhodopsin or other outer segment markers helps confirm proper localization

• Use of ROM-1 knockout tissue as a negative control is highly recommended

These technical considerations are essential for accurate interpretation of ROM-1 expression patterns in healthy and diseased retinal tissues .

How can ROM-1 antibodies be used to investigate tetraspanin complex stoichiometry in photoreceptors?

To investigate tetraspanin complex stoichiometry:

• Employ quantitative immunoblotting with purified recombinant standards to determine absolute protein amounts

• Use proximity ligation assays (PLA) to visualize and quantify ROM-1/PRPH2 interactions in situ

• Apply super-resolution microscopy techniques (STORM, PALM) with ROM-1 antibodies to map spatial organization

• Perform immunogold electron microscopy to determine precise ultrastructural localization

• Utilize mass spectrometry-based approaches to determine complex composition and stoichiometry

Studies have shown that the ratio of total tetraspanin (PRPH2 + ROM-1) to rhodopsin remains constant even when ROM-1 is knocked out, suggesting compensatory mechanisms to maintain proper stoichiometry in disc membranes .

What approaches can be used to study ROM-1 trafficking and membrane incorporation?

For investigating ROM-1 trafficking and membrane incorporation:

• Generate epitope-tagged ROM-1 constructs for live-cell imaging

• Use pulse-chase experiments with metabolic labeling to track protein maturation

• Apply cell surface biotinylation to quantify membrane-incorporated protein

• Utilize temperature-sensitive trafficking blocks to accumulate proteins at specific compartments

• Employ Brefeldin A or other trafficking inhibitors to assess secretory pathway dependence

• Create ROM-1-fluorescent protein fusions for FRAP (Fluorescence Recovery After Photobleaching) analysis

In vitro studies have shown that certain PRPH2 mutations (e.g., Y141C) cause retention in the endoplasmic reticulum, but co-expression with ROM-1 can rescue this phenotype, highlighting the importance of these interactions for proper trafficking .

How can multi-omics approaches incorporate ROM-1 antibody data for comprehensive disease modeling?

For integrated multi-omics approaches:

• Combine ROM-1 immunoprecipitation with mass spectrometry (IP-MS) to identify interaction partners

• Correlate ROM-1 protein levels (determined by quantitative immunoblotting) with transcriptomic data

• Integrate ROM-1 localization data from immunohistochemistry with spatial transcriptomics

• Map post-translational modifications of ROM-1 using phospho-specific antibodies combined with phosphoproteomics

• Apply systems biology approaches to model ROM-1 function in signaling networks

• Use weighted gene co-expression network analysis (WGCNA) to identify co-regulated gene modules

This integrated approach has been successfully applied to identify ROM-1 as a potential biomarker in intervertebral disc degeneration and to elucidate its role in retinal degenerative diseases .

What are the emerging applications of ROM-1 antibodies in personalized medicine research?

ROM-1 antibodies are increasingly valuable in personalized medicine research through:

• Screening patient-derived retinal organoids for ROM-1 expression and localization patterns

• Evaluating ROM-1/PRPH2 complex formation in patient samples to predict disease progression

• Monitoring ROM-1 expression changes in response to experimental therapeutics

• Identifying patient subgroups based on ROM-1 expression or complex formation patterns

• Developing ROM-1-targeted therapeutic approaches for specific genetic backgrounds

The finding that ROM-1 can convert Y141C-PRPH2-associated pattern dystrophy to retinitis pigmentosa highlights the potential of ROM-1 as both a disease modifier and therapeutic target in personalized medicine approaches .

How might advances in antibody engineering enhance ROM-1 research applications?

Emerging antibody technologies offer new opportunities for ROM-1 research:

• Development of conformation-specific antibodies that recognize only specific ROM-1 complex forms

• Generation of intrabodies for tracking ROM-1 in living cells without genetic modification

• Creation of single-domain antibodies with enhanced penetration for thick tissue sections

• Engineering of bispecific antibodies targeting ROM-1 and PRPH2 simultaneously

• Development of antibody-drug conjugates for targeted manipulation of ROM-1-expressing cells

• Application of nanobodies for super-resolution imaging of ROM-1 distribution

These advances could significantly enhance our ability to study ROM-1 biology and develop targeted therapeutic approaches for retinal degenerative diseases involving ROM-1 dysfunction .

What are the key unanswered questions in ROM-1 biology that antibody-based approaches might address?

Despite significant progress, several fundamental questions about ROM-1 biology remain:

• How do ROM-1 and PRPH2 precisely regulate disc diameter and incisure formation?

• What is the complete interactome of ROM-1 beyond PRPH2?

• How does ROM-1 contribute to non-retinal tissues and possible disease states?

• What molecular mechanisms explain the compensatory increase in PRPH2 when ROM-1 is absent?

• How do post-translational modifications regulate ROM-1 function?

• What is the evolutionary significance of ROM-1 in vertebrate vision?